# A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

> **NCT07570316** · PHASE3 · NOT_YET_RECRUITING · sponsor: **argenx** · enrollment: 230 (estimated)

## Conditions studied

- Graves' Disease
- Graves Disease

## Interventions

- **BIOLOGICAL:** Efgartigimod PH20 SC
- **OTHER:** Placebo PH20 SC

## Key facts

- **NCT ID:** NCT07570316
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2030-05
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570316, "A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07570316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*